cloning, there is no existing, effective mechanism for providing oversight or regulation, the FDA's intentions notwithstanding. Pending federal legislation, if passed, may force human reproductive cloning activities offshore or at least outside the country.
Nevertheless, the horse is out of the barn and the race is apparently on to produce the first human baby by somatic cell nuclear transfer (1, 2, 3) . Therefore, instead of taking a head in the sand position and insisting on a complete ban on all activities directed toward human reproductive cloning, it might be beneficial to seek middle ground in recognition of the day when the risk factors are greatly reduced and cloning is a proven tool in propagating animals.
First and foremost, I would want a commitment by all parties interested in human reproductive cloning to abide by the decisions of an international, bioethical advisory committee promoting the tenet of "do no harm." This committee would provide oversight for all aspects of human reproductive cloning research, including clinical trials, and might be analogous to the Human Fertilization and Embryology Commission (HFEC) in Britain. Second, I would want an agreement by all to maintain open laboratories, clinics, and data notebooks such that collective progress or failures in the field would be shared through workshops, publications, and the like. In other words, if human reproductive cloning is to go forward, it should do so just as any other legitimate research activity or clinical trial would, with public scrutiny. Parenthetically, this approach would almost certainly minimize the hype and hysteria produced and promoted by the media.
What could be done now that might be ethically acceptable, that could assess the risk of existing animal based protocols and begin the development of customized protocols for human use? Clearly, continued or increased activity in animal models including nonhuman primates would qualify, and this will occur. Somatic cell nuclear transfer has now been successful in a number of species including the sheep, cow, mouse, goat, and pig with a variety of cell types serving as the nuclear donor source. Many variations on a theme exist for somatic cell cloning based on experimentation involving hundreds of doctoral level scientists and tens of thousands of oocytes (4, 5) . And while the pregnancy rates following placement of NT embryos into synchronized hosts can be comparable to those achieved by application of the ARTs, term birth rates of normal animals are under 10% reflecting an astonishingly high fetal and neonatal loss rate. In the rhesus monkey, we have produced and transferred hundreds of NT embryos created with somatic cell nuclei without establishing a single pregnancy. Since no one wants to duplicate these adverse experiences in humans, additional animal studies are absolutely essential.
The cloning of human embryos for stem cell research has recently been approved in Britain with HFEC oversight. Given adequate justification, useful knowledge could undoubtedly arise from developmental studies of human NT embryos. This prediction is based on the known association between pregnancy, that is, in vivo developmental potential and in vitro development or the ability of embryos to reach the blastocyst stage within a defined time frame. With blastocyst development screens, one could determine which somatic cells are best, with perhaps, some understanding about why that is so, the optimal cell cycle stage for NT, and the appropriate timing of cytoplast activation. A threshold level of 30% reaching the blastocyst stage by Day 6 might be appropriate based on animal experimentation. The embryos could also be evaluated for chromosomal number irregularities by multicolor fluorescence in situ hybridization technology.
A characteristic of NT embryos is to arrest at or near the time of the maternal to embryonic transition in the regulation of development. In such cases, the donor nucleus may not be completely reprogrammed or it may not even function at all and, hence, there would be no chance of initiating a viable pregnancy. The use of nuclear donor cells transfected with a reporter gene construct could be employed to monitor activation of the embryonic genome at the appropriate time in NT embryos.
These cursory suggestions are for illustrative purposes only and are far from complete; nevertheless it is important to recognize that these questions along with a host of others must be answered before a reliable protocol can be developed for reproductive cloning in any species, our own included.
Finally, I recognize that a very low probability of success attended early IVF efforts and concerns proliferated with each new step in the evolving technology. Clinical application outpaced-and continues to do so-the development of an understanding of the underlying physiology. Just think of intracytoplasmic injection with round spermatids or cytoplasmic transfer. With time came increasing success, and fortunately, some assurance that applications of the ARTs were not associated with unacceptable outcomes, save the downsides of high order multiple pregnancy rates and the transmission of genetic conditions that presage azoospermia. With reproductive cloning, however, it is different. The warning signs are ominous and are all flashing red. Not only is there a low probability of consistent success but a significant probability of a highly undesirable outcome, the production of abnormal pregnancies, fetal wastage, and children with life threatening conditions. Not to mention that we have no assurances that age related abnormalities might occur later in life. Therefore, until the ethical concerns are more adequately addressed and control of the high fetal and neonatal wastage associated with somatic cell cloning is achieved in animals, human reproductive cloning efforts cannot abide by the "do no harm" mandate. They are unreasonable, undesirable, and destined to be relegated to the scientific fringe.
